

Special Issue

Advances in Ophthalmic Drug Discovery and Delivery: From Targets to Treatments

Message from the Guest Editor

Recent advancements in ophthalmic treatments have provided new hope for patients. Anti-VEGF therapies have transformed the management of retinal diseases, significantly improving outcomes for conditions such as wet AMD and diabetic macular edema. More recently, complement inhibition has emerged as a promising strategy for geographic atrophy, an advanced form of AMD. Despite these breakthroughs, many challenges remain in drug delivery, durability, and efficacy, underscoring the need for continued innovation.

This Special Issue invites original research and comprehensive reviews focusing on advances in ophthalmic drug discovery and delivery. We welcome contributions on topics including novel drug targets, innovative delivery systems, sustained-release formulations, gene- and cell-based therapies, and artificial intelligence-driven drug development. By bringing together cutting-edge research, this Special Issue aims to foster new perspectives and transformative approaches in the fight against vision loss.

Guest Editor

Dr. Hongli Wu

Department of Pharmaceutical Sciences, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA

Deadline for manuscript submissions

30 September 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/232282

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)